apollo sciences cbd

Over the past several years, FDA has issued several warning letters to firms that market unapproved new drugs that allegedly contain cannabidiol (CBD). As part of these actions, FDA has tested the chemical content of cannabinoid compounds in some of the products, and many were found to not contain the levels of CBD they claimed to contain. It is important to note that these products are not approved by FDA for the diagnosis, cure, mitigation, treatment, or prevention of any disease. Consumers should beware purchasing and using any such products.

The genus cannabis includes two species that produce useful amounts of psychoactive cannabinoids: Cannabis sativa and Cannabis indica. A third strain, Cannabis ruderalis, has few psychoactive properties. Cannabis contains many compounds; it is postulated that the C. sativa plant contains over 400 compounds, approximately 60 of which are active. [5],[6],[7] The active compounds are collectively known as cannabinoids, and their potency is variable depending on the species and extraction process. There are three compounds that have been isolated and identified as the most potent: Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannibinol. In the 1960s, THC was established as the cannabinoid primarily responsible for the psychoactive properties of marijuana and the one responsible for most, though not all, of the pharmacologic effects of cannabis. [3],[4],[8],[9]

Source of Support: None, Conflict of Interest: None

A number of neurotransmitters are affected by CB1, including acetylcholine, norepinephrine, dopamine, serotonin, gamma-aminobutyric acid, glutamate, and D-aspartate. [5] These interactions account for many of marijuana's effects on pleasure, memory, thought, concentration, sensory and time perception, and coordination. The CB2 receptors are present mainly on immune cells and peripheral tissues and can have inflammatory, immunosuppressive, and antinociceptive activities. [5],[10] The definitive pharmacologic actions of CB2 receptor binding have yet to be determined, but recently, CB2 receptors were identified in microglia. [3]

Correspondence Address:
Pushpendra Nath Renjen
C-85, Anand Niketan, New Delhi – 110 021; Institute of Neurosciences, Indraprastha Apollo Hospitals, Sarita Vihar, New Delhi-110 076

The use of medical marijuana has received a great deal of public attention in recent years. Marijuana has a long history as an illicit drug, with outspoken proponents and opponents both attempting to influence public opinion and policy. The complex background may color perceptions of medical marijuana use in the eyes of some neurology patients, necessitating an explanation of the effectiveness, side effects, risks, and benefits.